StudyFinder

EXPANDED ACCESS PROGRAM TO TREAT PATIENTS WITH PREVIOUSLY TREATED METASTATIC PANCREATIC ADENOCARCINOMA WITH DARAXONRASIB

Status: Recruiting

The purpose of this expanded access program is to provide the investigational medication daraxonrasib to adults with metastatic pancreatic cancer who have received previous treatment, have no satisfactory treatment options, and are unable to participate in a daraxonrasib clinical trial.

I'm interested
Visit the Study Website

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 years of age or older able to take oral medication
• diagnosed with metastatic pancreatic cancer that has grown or spread after previous treatment
• received at least one prior treatment for metastatic pancreatic cancer
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• pancreatic cancer that has spread to the brain or central nervous system
• currently receiving another cancer treatment
• significant heart disease or an active, uncontrolled infection
• major surgery within the past 28 days
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions:

Cancer

Keywords:

Clinics and Surgery Center, CSC, Clinics and Surgery Center (CSC), pancreatic adenocarcinoma, pancreatic cancer, cancer

Study Contact: Simone Veum - veum0015@umn.edu
Principal Investigator: Alex Tsai
IRB Number: STUDY00028794
See this study on ClinicalTrials.gov

Back